|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Rabin Medical Center |
|---|---|
| Information provided by: | Rabin Medical Center |
| ClinicalTrials.gov Identifier: | NCT00445250 |
Purpose
Examining the hypothesis that protecting keratinocytes by calcipotriol can prevent in-vivo cutaneous side effect in patients receiving radiotherapy to the breast.
To check the connection between the skin effect of radiotherapy and different parameters including diseases such as diabetes and lupus, use of medications, allergies, weight, habits, size of the irradiated breast, previous chemotherapy treatment and exposure to sunlight.
| Condition | Intervention | Phase |
|---|---|---|
|
Radiodermatitis |
Drug: Calcipotriol |
Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase 2 Study of the Role of Calcipotriol as Radioprotector of Skin in Women Receiving Radiotherapy Treatment to the Breast. |
| Estimated Enrollment: | 50 |
STUDY PROTOCOL
Fifty women diagnosed with breast cancer planned to receive adjuvant radiotherapy, will participate in the study. About 15 minutes after receiving the daily radiation dose fraction, a cream containing an active vitamin D analogue will be applied to half of the breast with inspection of a nurse. The other half of the breast will have a standard cream applied . During the days that radiotherapy is not administered the standard cream will be applied to both halves of the breast in a case of strong reaction to radiotherapy (e.g. strong erythema, painful tenderness etc.)The adverse skin effects will be assessed according to the following criteria:
. an assessment by a physician and a nurse according to the RTOG score (6).
As follows:
Grade 0 – no reaction. Grade 1 - light erythema dry peeling, decrease in sweat production. Grade 3 – extensive moist peeling, pitting edema. Grade 4 – ulcers, bleeding and necrosis.
Safety report will be sent to the local independent ethics committee after the examination of the first ten patients.
The protective effect of the cream containing calcipotriol will be compared to the standard treatment and analyzed statistically using the parameters mention above. The relation between the background disease, medications, allergies, weight, habits, size of the irradiated breast, sun exposure, previous chemotherapy treatment and exposure to sunlight and the skin reaction will be evaluated.
INCLUSION CRITERIA
EXCLUSION CRITERIA
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Eyal Fenig, M.D. | 97239377964 | efenig@clalit.org.il |
| Contact: Ofer Purim, M.D. | 97239377973 | oferp@clalit.org.il |
| Israel | |
| Rabin Medical Center | Not yet recruiting |
| Petach Tiqva, Israel, 49100 | |
| Contact: Eyal Fenig, M.D. 97239377964 efenig@clalit.org.il | |
| Contact: Ofer Purim, M.D. 97239377973 oferp@clalit.org.il | |
| Principal Investigator: Eyal Fenig, M.D. | |
| Sub-Investigator: Ofer Purim, M.D. | |
| Sub-Investigator: Amir Abramovich, M.D. | |
| Principal Investigator: | Eyal Fenig, M.D. | Rabin Medical Center |
More Information
| ClinicalTrials.gov Identifier: | NCT00445250 History of Changes |
| Other Study ID Numbers: | 004253 |
| Study First Received: | March 7, 2007 |
| Last Updated: | March 7, 2007 |
| Health Authority: | Israel: Ministry of Health |
|
Calcipotriol Breast Cancer Radiotherapy Radiodermatitis in Breast Cancer |
|
Radiodermatitis Dermatitis Skin Diseases Radiation Injuries Wounds and Injuries Calcipotriene Calcitriol Dermatologic Agents Therapeutic Uses Pharmacologic Actions |
Vitamins Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents Calcium Channel Agonists Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Vasoconstrictor Agents Cardiovascular Agents |